Cardiac effects of noncardiac neoplasms.
Clinically significant cardiovascular abnormalities may occur as secondary manifestations of noncardiac neoplasms. The principal cardiac effects of noncardiac tumors include the direct results of metastases to the heart or lungs, the indirect effects of circulating tumor products (causing nonbacterial thrombotic endocarditis, myeloma-associated amyloidosis, pheochromocytoma-associated cardiac hypertrophy and myofibrillar degeneration, and carcinoid heart disease), and the undesired cardiotoxicities of chemotherapy and radiotherapy.
D000686:Amyloidosis / Q000209:etiology; D000970:Antineoplastic Agents / Q000009:adverse effects; D001808:Blood Vessels / Q000473:pathology; D002276:Carcinoid Tumor / Q000556:secondary; D004696:Endocarditis / Q000209:etiology; D006321:Heart / Q000187:drug effects / Q000503:physiopathology / Q000528:radiation effects; D006331:Heart Diseases / Q000209:etiology; D006335:Heart Injuries / Q000209:etiology; D006338:Heart Neoplasms / Q000556:secondary; D006349:Heart Valve Diseases / Q000209:etiology; D006801:Humans; D008175:Lung Neoplasms / Q000473:pathology; D009101:Multiple Myeloma / Q000150:complications; D009206:Myocardium / Q000473:pathology*; D009369:Neoplasms / Q000150:complications / Q000473:pathology* / Q000503:physiopathology / Q000628:therapy; D009360:Neoplastic Cells, Circulating / Q000473:pathology; D010496:Pericardium; D010673:Pheochromocytoma / Q000150:complications; D011832:Radiation Injuries; D013927:Thrombosis / Q000209:etiology
D000970:Antineoplastic Agents